# US 2026/0151487 A1 · Photodynamic therapy comprising two light exposures at different wavelengths

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0151487 A1
- Document ID: US20260151487A1
- Status: Published application
- Kind: A1
- Application number: 19/456,929
- Filed: 2026-01-22
- Published: 2026-06-04
- Earliest claimed: 2023-03-22
- Assignees: Biofrontera Bioscience GmbH
- Applicants: Biofrontera Bioscience GmbH
- Inventors: Hermann LÜBBERT
- Web page: https://patentgrep.com/patent/US20260151487A1

## CPC

- A61K 41/0061: {5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61N 5/0616: {Skin treatment other than tanning}
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C07C 229/22: the carbon skeleton being further substituted by oxygen atoms
- C07D 487/22: in which the condensed system contains four or more hetero rings
- A61N 2005/0663: {Coloured light}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps: (a) topical application or subcutaneous injection of said composition to an area of the skin of said patient, (b) exposure of at least said area of the skin to light with a wavelength spectrum similar or identical to sun light for a duration of 30 min to 5 hours, and (c) exposure of at least said area of the skin to light of a wavelength spectrum comprising only one maximum in the absorbance spectrum of said photosensitizer as well as to methods of treating dermatological disease using the outlined steps and kits of parts comprising such compositions and light sources suitable to apply the respectively indicated light.

## Claims

### Claim 1

A composition comprising a photosensitizer for prevention or treatment of a dermatological disease in a patient, wherein the composition is used in the following order of steps:
(a) topical application or subcutaneous injection of said composition to an area of the skin of said patient; and
(b) exposure of at least said area of the skin to light with a wavelength spectrum of 570 nm to 780 nm or 570 nm to 650 nm for a duration of 1 to 3 hours, wherein the light results in a radiant exposure of 15-40 J/cm2.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the duration of step (b) is 1 to 2 hours.

### Claim 3 (depends on 1)

The composition of claim 1, wherein there is a residence time interval subsequent to step (a) and prior to step (b) of 5 to 60 minutes.

### Claim 4 (depends on 1)

The composition of claim 1, wherein after application of the composition, the treated area is covered with an occlusive dressing.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the occlusive dressing is light-tight.

### Claim 6 (depends on 4)

The composition of claim 4, wherein the treated area is covered for 30 minutes.
